Invitation to join the CLOSZE Panel (Clozapine in Schizophrenia Experts)<\/h2>\n<\/div><\/div><\/div>![\"\"](\"https:\/\/curesz.org\/wp-content\/uploads\/2023\/06\/Meyer-cropped-1.jpg\")
One of the major initiatives of CURESZ is to promote the use of clozapine, which is vastly underused. Clozapine is the only medication approved by the FDA for delusions and\/or hallucinations that improve minimally or not at all with adequate trials of two antipsychotic drugs, and for patients with schizophrenia who also have suicidal thoughts or behavior. It is estimated that of the 2.5 million persons living with schizophrenia in the U.S. about 500,000 have not had a chance to receive clozapine to possibly recover and overcome their vocational and social disability. To increase the chance that a patient suffering from treatment-resistant or refractory schizophrenia can receive a trial of clozapine, CURESZ is assembling a panel of clozapine experts around the U.S. to serve as a referral base.<\/p>\n
We hope to get up to 200 experts to join this national panel of experts, which we are calling CLOSZE (Clozapine in Schizophrenia Experts<\/a>). The mission is to \u201cclose\u201d the door on disability among persons living with schizophrenia. Jonathan Meyer, MD<\/a>, Deputy Editor of Current Psychiatry, a member of the Board of Trustees of the CURESZ Foundation, and a national clozapine expert, will serve as the Chair of the CLOSZE Panel.<\/p>\nInterested colleagues who would like to join CLOSZE, please enter your name, email, office phone and office address on the form above, and we will organize a list by state and city so that patients and families around the country can contact the nearest expert to get an evaluation for a possible clinical trial.<\/p>\n<\/div><\/div><\/div>
One of the major initiatives of CURESZ is to promote the use of clozapine, which is vastly underused. Clozapine is the only medication approved by the FDA for delusions and\/or hallucinations that improve minimally or not at all with adequate trials of two antipsychotic drugs, and for patients with schizophrenia who also have suicidal thoughts or behavior. It is estimated that of the 2.5 million persons living with schizophrenia in the U.S. about 500,000 have not had a chance to receive clozapine to possibly recover and overcome their vocational and social disability. To increase the chance that a patient suffering from treatment-resistant or refractory schizophrenia can receive a trial of clozapine, CURESZ is assembling a panel of clozapine experts around the U.S. to serve as a referral base.<\/p>\n
We hope to get up to 200 experts to join this national panel of experts, which we are calling CLOSZE (Clozapine in Schizophrenia Experts<\/a>). The mission is to \u201cclose\u201d the door on disability among persons living with schizophrenia. Jonathan Meyer, MD<\/a>, Deputy Editor of Current Psychiatry, a member of the Board of Trustees of the CURESZ Foundation, and a national clozapine expert, will serve as the Chair of the CLOSZE Panel.<\/p>\n Interested colleagues who would like to join CLOSZE, please enter your name, email, office phone and office address on the form above, and we will organize a list by state and city so that patients and families around the country can contact the nearest expert to get an evaluation for a possible clinical trial.<\/p>\n<\/div><\/div><\/div>